5 results about "Mononucleosis" patented technology

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

The application discloses a prediction model for diagnosing infectious mononucleosis in children and a construction method thereof. The application adopts single factor analysis and logistic stepwise regression to screen independent influencing factors by using confirmed IM inpatient cases and suspected IM but EBV-DNA negative child cases, and adopts multiple factor regression to screen six independent influencing factors of age, ALB, GLB, PLT, LYMPH# and LYMPH% to construct a diagnosis model. Researches show that in the confirmed diagnosis scene, the multi-index combined model with blood routine and liver function has excellent diagnosis efficiency (AUC=0.986), realizes the ideal balance of high sensitivity and high specificity, provides a hierarchical tool for the precise diagnosis of IM in different clinical scenes, and is suitable for the precise diagnosis of inpatient children.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

This invention provides a composition comprising an LSD1 inhibitor and 1,25(OH)2D3 and its application in the treatment of acute monocytic leukemia. The composition provided by this invention can induce AML-M5 cell differentiation, achieving the therapeutic effect on acute monocytic leukemia while avoiding the side effect of hypercalcemia caused by high doses of 1,25(OH)2D3.